Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 184

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 184
---
 specified circumstances. Though we continue to assess the magnitude of these costs, additional unanticipated costs may be incurred in the Kineta Merger and the integration of our business with Kineta’s business. 

We may be the target of securities class action and stockholder lawsuits which could result in substantial costs and may delay or prevent the Kineta Merger from being completed. 

Securities class action lawsuits and stockholder lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Kineta Merger, then that injunction may delay or prevent the Kineta Merger from being completed, which may adversely affect our, or, if the Kineta Merger is completed but delayed, the combined company’s business, financial position and results of operations. As 

80

of the date of this Annual Report, no such lawsuits have been filed in connection with the Kineta Merger and we cannot predict whether any will be filed. 

General Risk Factors 

Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.

Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we ultimately compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.

Our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for our products, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice, or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.

Our business could be adversely affected